Back to top

gene-therapy: Archive

Zacks Equity Research

Novartis to License VYGR's Capsid for Gene Therapy in Neurology

NVS has decided to license a novel capsid generated from Voyager's TRACER platform for use in a gene therapy program against an undisclosed rare neurologic disease target.

NVSPositive Net Change VYGRNegative Net Change KRYSNegative Net Change FULCNegative Net Change